Physician profile
Mark S Box
NPI 1477604817
$303,762.11
in general payments reported to CMS, 2019-2025
64 companies · $35K in 2025
The $35K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86K · 2020: $28K · 2021: $48K · 2022: $45K · 2023: $32K · 2024: $30K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60K · Food and Beverage: $18K · Consulting Fee: $11K · Travel and Lodging: $7,162 · Education: $481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,662.50 |
| Food and Beverage | $18,474.96 |
| Consulting Fee | $11,277.50 |
| Travel and Lodging | $7,162.28 |
| Education | $480.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $55,777.29 | 2019-2025 | Rinvoq, Skyrizi, Ubrelvy |
| Glaxosmithkline, LLC. | $53,480.30 | 2019-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $40,420.53 | 2021-2025 | Saphnelo, Evusheld, Flumist Quadrivalent |
| Pfizer INC. | $40,180.79 | 2019-2025 | |
| Amgen INC. | $34,314.54 | 2019-2025 | Tavneos, Krystexxa, Enbrel |
| E.R. Squibb & Sons, L.L.C. | $16,449.11 | 2019-2025 | Orencia |
| Novartis Pharmaceuticals Corporation | $13,409.72 | 2019-2025 | |
| Genzyme Corporation | $6,123.09 | 2019-2025 | |
| Mallinckrodt Enterprises LLC | $5,710.33 | 2019 | |
| Gilead Sciences, INC. | $5,469.04 | 2019-2020 | |
| Genentech USA, INC. | $5,088.93 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Regeneron Healthcare Solutions, INC. | $3,458.38 | 2019 | |
| Horizon Therapeutics Plc | $3,375.69 | 2019-2023 | Krystexxa |
| Janssen Scientific Affairs, LLC | $3,296.40 | 2019-2025 | Tremfya |
| Ucb, INC. | $2,908.47 | 2019-2025 | Bimzelx, Cimzia |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,369.55 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Janssen Global Services, LLC | $2,000.00 | 2021 | |
| Fresenius Kabi USA, LLC | $1,806.02 | 2022-2025 | Idacio |
| Lilly USA, LLC | $1,588.75 | 2019-2025 | Taltz, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,343.37 | 2019-2024 | Ofev, Spevigo, Cyltezo |
| Mallinckrodt Hospital Products INC. | $805.14 | 2020-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $624.32 | 2022-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $488.15 | 2021-2024 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $421.96 | 2019-2025 | Strensiq, Ultomiris |
| Johnson & Johnson Health Care Systems INC. | $256.00 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $222.04 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Organon LLC | $200.94 | 2023-2025 | Renflexis, Hadlima |
| Hospira, INC. | $198.89 | 2022-2025 | |
| United Therapeutics Corporation | $193.35 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $171.42 | 2019-2024 | |
| Tersera Therapeutics LLC | $125.46 | 2019-2025 | Quzyttir |
| Sobi, INC | $125.44 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $123.62 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $93.73 | 2020-2022 | |
| Sandoz INC. | $89.69 | 2024-2025 | Hyrimoz |
| Kyowa Kirin, INC. | $84.13 | 2024-2025 | Crysvita |
| Radius Health, INC. | $82.38 | 2019-2025 | Tymlos |
| Genentech, INC. | $82.23 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $76.81 | 2023 | Arcalyst |
| Grifols USA, LLC | $71.41 | 2023-2024 | Gamunex-C |
| Kiniksa Pharmaceuticals International, Plc | $58.14 | 2024 | Arcalyst |
| Invivyd INC | $57.17 | 2025 | Pemgarda |
| Novo Nordisk INC | $51.83 | 2023-2024 | Wegovy, Saxenda |
| Bioventus LLC | $44.86 | 2019 | |
| Mylan Institutional INC. | $44.46 | 2023 | Hulio |
| Octapharma USA, INC. | $34.02 | 2024-2025 | Octagam Immune Globulin (Human) |
| Eisai INC. | $30.24 | 2020-2025 | |
| Antares Pharma, INC. | $29.18 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.27 | 2022 | |
| Ironwood Pharmaceuticals, INC | $26.65 | 2020 | |
| Celgene Corporation | $23.32 | 2019 | |
| Pacira Therapeutics, INC. | $23.26 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $21.91 | 2024 | Simlandi |
| Vertex Pharmaceuticals Incorporated | $21.58 | 2025 | |
| Upsher-Smith Laboratories LLC | $18.83 | 2020 | |
| Celltrion USA INC. | $18.68 | 2023 | Yuflyma |
| Daiichi Sankyo INC. | $17.89 | 2019 | |
| Almatica Pharma LLC | $17.81 | 2025 | Teriparatide |
| Tonix Medicines, INC. | $16.57 | 2025 | Tonmya |
| Idorsia Pharmaceuticals US INC | $15.67 | 2023 | Quviviq |
| Boston Scientific Corporation | $15.47 | 2020 | |
| Depuy Synthes Sales INC. | $14.49 | 2020 | |
| Medexus Pharma, INC. | $12.26 | 2019 | |
| Fidia Pharma USA INC. | $12.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Box listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.